The SUNRISE program consists of two primary studies, SUNRISE-1 and SUNRISE-2, each targeting an enrollment of 560 participants. Researchers will measure the percent change in body weight from baseline for patients receiving once-daily doses of 27.5 mg, 35 mg, 55 mg, or a placebo. While SUNRISE-1 focuses on obese or overweight adults with at least one weight-related comorbidity, SUNRISE-2 is tailored specifically for those living with type 2 diabetes.
Viking Therapeutics Launches Phase 3 Trials for Oral Obesity Drug
Viking Therapeutics has officially launched its SUNRISE Phase 3 clinical program, testing an oral version of its dual GLP-1 and GIP receptor agonist, VK2735. The study aims to evaluate the drug's efficacy and safety in adults struggling with obesity, both with and without type 2 diabetes, over a 68-week period.
This expansion into late-stage testing follows positive results from the Phase 2 VENTURE-Oral Dosing study. In that trial, participants experienced weight loss of up to 12.2% after 13 weeks. CEO Brian Lian noted that the oral formulation is designed to offer flexibility for long-term weight management, potentially serving as either an induction therapy or a maintenance tool. Viking is simultaneously advancing its subcutaneous formulation of the drug through the separate VANQUISH registration program, which has already fully enrolled approximately 5,500 patients across two studies.
Comments (0)
No comments yet. Be the first!